Thiri Zaw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thiri Zaw has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Alexander James
Developmental and Stem Cell Biology Division, Victor Chang Cardiac Research Institute, Sydney, Australia
1 shared publication - Amandeep Kaur
Medicinal Chemistry Monash Institute of Pharmaceutical Sciences Monash University Melbourne VIC Australia
1 shared publication - Ashleigh Van Oosterum
Life Sciences and Health, Faculty of Science, Charles Sturt University, Wagga Wagga, NSW, 2650, Australia
1 shared publication - Bashar Mohammed Thejer
School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW, 2650, Australia
1 shared publication - Bing Liu
Neurodegenerative Disease section, Iggy Get Out (IGO), Boundary street, Darlinghurst NSW 2010. Sydney. Australia
1 shared publication - Craig Peter Coorey
School of Medicine Western Sydney University Campbelltown Australia
1 shared publication
Latest Publications
- Open Access
- 29 March 2021
- Published by LIDSEN Publishing Inc in OBM Geriatrics
- Vol. 05 (01) , 1-21
Molecular Basis of Allogeneic Pluripotent Stem Cell Treatment of a Patient with Sporadic ALS
There are no curative strategies for ALS, and as a result the alternative therapies are gaining ground, in particular the stem cell-based therapies which hold a promising future. Here we describe an ALS patient, who by choice, received allogeneic human cord-blood derived multipotent stem cells (MSC) intravenously and intrathecally. This is the first snapshot of pre-and post-stem cell transplantation in an ALS patient through transcriptomic, epigenomic, and proteomic follow-up elucidating the effect of stem cells in ALS. Although new CSF proteins (FGA, B2M, FN1 and IGFBP3) were observed, but more work is needed to fully elucidate the effect based on larger cohorts in a clinical trial setting. These analyses may serve as a future guide to both scientists and clinicians alike in defining the utility of such cells in ALS treatment.
- 29 March 2021
- Published by LIDSEN Publishing Inc in OBM Geriatrics
- Vol. 05 (01) , 1-21
Open AccessMolecular Basis of Allogeneic Pluripotent Stem Cell Treatment of a Patient with Sporadic ALS
There are no curative strategies for ALS, and as a result the alternative therapies are gaining ground, in particular the stem cell-based therapies which hold a promising future. Here we describe an ALS patient, who by choice, received allogeneic human cord-blood derived multipotent stem cells (MSC) intravenously and intrathecally. This is the first snapshot of pre-and post-stem cell transplantation in an ALS patient through transcriptomic, epigenomic, and proteomic follow-up elucidating the effect of stem cells in ALS. Although new CSF proteins (FGA, B2M, FN1 and IGFBP3) were observed, but more work is needed to fully elucidate the effect based on larger cohorts in a clinical trial setting. These analyses may serve as a future guide to both scientists and clinicians alike in defining the utility of such cells in ALS treatment.
- Open Access
PGRMC1 phosphorylation and cell plasticity 1: glycolysis, mitochondria, tumor growth
SUMMARY: Progesterone Receptor Membrane Component 1 (PGRMC1) is expressed in many cancer cells, where it is associated with detrimental patient outcomes. It contains phosphorylated tyrosines which evolutionarily preceded deuterostome gastrulation and tissue differentiation mechanisms. Here, we demonstrate that manipulating PGRMC1 phosphorylation status in MIA PaCa-2 (MP) cells imposes broad pleiotropic effects. Relative to parental cells over-expressing hemagglutinin-tagged wild-type (WT) PGRMC1-HA, cells expressing a PGRMC1-HA-S57A/S181A double mutant (DM) exhibited reduced levels of proteins involved in energy metabolism and mitochondrial function, and altered glucose metabolism suggesting modulation of the Warburg effect. This was associated with increased PI3K/Akt activity, altered cell shape, actin cytoskeleton, motility, and mitochondrial properties. An S57A/Y180F/S181A triple mutant (TM) indicated the involvement of Y180 in PI3K/Akt activation. Mutation of Y180F strongly attenuated mouse xenograft tumor growth. An accompanying paper demonstrates altered metabolism, mutation incidence, and epigenetic status in these cells, indicating that PGRMC1 phosphorylation strongly influences cancer biology.
Open AccessPGRMC1 phosphorylation and cell plasticity 1: glycolysis, mitochondria, tumor growth
SUMMARY: Progesterone Receptor Membrane Component 1 (PGRMC1) is expressed in many cancer cells, where it is associated with detrimental patient outcomes. It contains phosphorylated tyrosines which evolutionarily preceded deuterostome gastrulation and tissue differentiation mechanisms. Here, we demonstrate that manipulating PGRMC1 phosphorylation status in MIA PaCa-2 (MP) cells imposes broad pleiotropic effects. Relative to parental cells over-expressing hemagglutinin-tagged wild-type (WT) PGRMC1-HA, cells expressing a PGRMC1-HA-S57A/S181A double mutant (DM) exhibited reduced levels of proteins involved in energy metabolism and mitochondrial function, and altered glucose metabolism suggesting modulation of the Warburg effect. This was associated with increased PI3K/Akt activity, altered cell shape, actin cytoskeleton, motility, and mitochondrial properties. An S57A/Y180F/S181A triple mutant (TM) indicated the involvement of Y180 in PI3K/Akt activation. Mutation of Y180F strongly attenuated mouse xenograft tumor growth. An accompanying paper demonstrates altered metabolism, mutation incidence, and epigenetic status in these cells, indicating that PGRMC1 phosphorylation strongly influences cancer biology.